ARCHIVES

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

This article is from The Cancer Letter archive.

Vol. 30 No. 21 | May 21, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Dispute GAO Charge That Cancer Control Contracts Were Mishandled

August 15, 1980

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

October 26, 2001

NIH Deputy Director Ruth Kirschstein Plans Transition To Senior Advisor

October 4, 2002

Multi-Gene Assay Predicts Recurrence In Newly Diagnosed Breast Cancer

December 26, 2003

Community Assn. Plan Meeting In DC On Program Problems

November 29, 1974

Cancer, AIDS Patient Advocates List Drug Development Concerns

May 12, 1989